rejuvant life tabs

Longevity supplements report: PDLH profile

Latest articles

A single source for longevity nutrition data

Edamam co-founder talks bringing nutrition into the digital world and seeking funding for expansion in food as medicine. When it comes to food nutrition data,...

The Sheekey Science Show – Senotherapeutics

Senotherapeutics are therapeutics strategies that target cellular senescence. They can work by killing senescent cells (senolytics), inhibiting the proinflammatory secretory phenotype of senescent cells (senomorphics)...

Michael Greve commits €300m for rejuvenation start-ups

The founder of Forever Healthy has committed €300 million to advance rejuvenation biotech start-ups – plus exclusive insights from Michael Greve. Michael Greve, founder of...

Capsida Biotherapeutics emerges from stealth with $140m

Versant Ventures and Westlake Village BioPartners launch next-generation gene therapy company with $50m series A; AbbVie collaboration provides $90m for gene therapies for CNS...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

A single source for longevity nutrition data

Edamam co-founder talks bringing nutrition into the digital world and seeking funding for expansion in food as medicine. When it comes to food nutrition data,...

The Sheekey Science Show – Senotherapeutics

Senotherapeutics are therapeutics strategies that target cellular senescence. They can work by killing senescent cells (senolytics), inhibiting the proinflammatory secretory phenotype of senescent cells (senomorphics)...

Michael Greve commits €300m for rejuvenation start-ups

The founder of Forever Healthy has committed €300 million to advance rejuvenation biotech start-ups – plus exclusive insights from Michael Greve. Michael Greve, founder of...
Rejuvant

The company behind Rejuvant, which partnered with the Buck Institute for Research on Aging on its calcium alpha-ketoglutarate longevity supplement.

Over the coming weeks, we will be bringing you extracts of 11 company profiles from our Longevity Supplements Report. Each profile includes an assessment of Pre-Clinical and Clinical Studies, Safety and Risks, Target Market and Success Factors and the target Hallmark(s) of Aging for one of their key products.

We also study each of the companies’ IP, team, UVP, product efficacy, competitive advantage, runway and inflection point, and much more. Here’s the lowdown on Ponce de Leon Health.

To view a full size version of PDL’s profile please click here.

Longevity-Supplements 1.0 PDHL Summary

Ponce de Leon Health Inc. (PDLH) is a science driven longevity company, specifically focused on reversing epigenetic aging, as measured by DNA methylation testing. The company has spent approximately $10m over the last 7 years developing Rejuvant® by partnering with the Buck Institute for Research on Aging. The Buck Institute has performed several multi-year mouse trials for PDLH, testing combinations of compounds commonly believed to extend mammal lifespan. Nearly all have no effect individually and are not additive in combination. This thorough, long and expensive process resulted in the creation of Rejuvant.

Elevant

Tom Weldon is the founder, chairman and CEO of PDLH. He has created over $2b of shareholder exit value in the companies he has personally founded. As an entrepreneur and venture capitalist, he has been fascinated with the longevity space for over a decade. Several years ago, he joined the advisory board for the Buck Institute to get closer to the science. After reviewing the individual scientific programmes underway there, he concluded that their development timescales were too long and that they were also expensive. Weldon wanted to develop and commercialise a product that could benefit his parents, who were already in their 80s. This led to the development of a business strategy focused on a non-prescription solution comprised of known dietary supplement and food ingredients, which could be brought to market quickly, and sold at a price-point that is equivalent to a daily coffee beverage at a national chain. As Dr Brian Kennedy, Chief Scientific Officer at PDLH, eloquently stated “We are not looking to extend the lives of billionaires, but to extend the lives of billions.”

Rejuvant is a patent pending (8 patents filed), male and female formulations and is the result of years of development in three different models – including humans. PDLH consider it to be the only commercial product that has shown to increase lifespan, disproportionately extend healthspan and compress morbidity in the mouse model. This work was published in Cell Metabolism in September 2020 and stated that pilot research data has shown that Rejuvant can reverse biologic aging, as measured by DNA methylation testing. The company sells its product exclusively direct to consumer on the internet and is available for purchase at Rejuvant.com. However, it is understood to be in active discussions about exclusive distribution rights in several foreign countries. The company is also in discussions with multiple global branded consumer product companies about various relationship agreements. PDLH does not publicly disclose any sales or profit figures.

PDLH manufactures Rejuvant LifeTabs®, containing LifeAKG™, in the US. LifeAKG is produced in an FDA registered pharmaceutical cGMP, ISO-9001 and ISO-1401 facility. PDLH states that its product contains the highest purity of commercially available Calcium Alpha-Ketoglutarate. The LifeAKG and nutrients are tableted with a proprietary, controlled-release matrix, to ensure optimal absorption and best replicate conditions of the study conducted by the scientific team at the Buck Institute.

Elevant

Access to the report and a FREE executive summary can be found here, and check out our other supplements company profiles here.

Comment on this article

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
Rejuvant

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Supplement report

Related articles

Michael Greve commits €300m for rejuvenation start-ups

The founder of Forever Healthy has committed €300 million to advance rejuvenation biotech start-ups – plus exclusive insights from Michael Greve. Michael Greve, founder of...

Capsida Biotherapeutics emerges from stealth with $140m

Versant Ventures and Westlake Village BioPartners launch next-generation gene therapy company with $50m series A; AbbVie collaboration provides $90m for gene therapies for CNS...

Longevity supplements report: Vitalic

Currently in stealth, Vitalic is on a mission to transition longevity from the early adopters on to a mass market through best-in-class marketing. Over the...

FOXO exclusively licenses epigenetic clocks from UCLA

FOXO Technologies' exclusive licence of epigenetic clocks PhenoAge and GrimAge from UCLA could be an insurance game-changer. FOXO Technologies Inc has announced the licence of...

Longevity investment: small sums behind big ideas

Sonia Arrison talks about her journey to becoming an early stage investor and what longevity means to her. While longevity is now seeing increasing interest...
Supps report ad middle